Prevalence and risk factors of hepatitis B infection in injection drug users, Tehran (2001-2002)

Hepatitis Monthly

Volumn 8, Issue 1, 2008, Pages 29-33

  Tavakkoli, Hamid ^a   Mir Nasseri, Mohammad Mahdi ^b   Poustchi, Hossein ^b   Afshar, Parviz ^c   Motalebi, Mohammad Nabi ^b   Mohammadkhani, Ashraf ^b   Malekzadeh, Reza ^b  

^a ALZAHRA UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Health Correction and Rehabilitation of Iran Prisons   (Iran)

Author keywords

Hepatitis B; Injection drug user; Risk factor

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ADDICTION; ADOLESCENT; ADULT; AGE; ANAMNESIS; ARTICLE; BISEXUALITY; BLOOD SAMPLING; BLOOD TRANSFUSION; EDUCATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; IRAN; JAUNDICE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREVALENCE; PRISON; PRISONER; QUESTIONNAIRE; RISK FACTOR; SEROPREVALENCE; SEXUAL BEHAVIOR; TATTOO;

EID: 44949188666     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Tefanova V, Tallo T, Kutsar K, Priimgi L. Urgent action needed to stop spread of hepatitis B and C in Estonian drug users. Euro Surveill 2006; 11: E0601263.
2. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995; 274: 1201-8.
3. Borhanmanesh F, Behforouz N, Sanadizadeh M, Soleimani M. Hepatitis-associated antigen in patients with liver diseases and in rural population of Iran. Increased incidence in men. Acta Hepatogastroenterol (Stuttg) 1979; 26: 358-63.
4. Ghanaat J, Sadeghian A, Ghazvini K, Nassiri MR. Prevalence and risk factors for hepatitis B virus infections among STD patients in northeast region of Iran. Med Sci Monit 2003; 9: CR91-4.
5. Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005; 2: 50-7.
6. Farzadegan H, Harbour C, Ala F. The prevalence of hepatitis B surface antigen and its antibody in blood donors and high risk groups in Iran. Vox Sang 1979; 37: 182-6.
7. Jahani MR, Motevalian SA, Mahmoodi M. Hepatitis B carriers in large vehicle drivers of Iran. Vaccine 2003; 21: 1948-51.
8. Amini S, Mahmoodi MF, Andalibi S, Solati AA. Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: a population based study. J Trop Med Hyg 1993; 96: 277-87.
9. Ghavanini AA, Sabri MR. Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors in the Islamic Republic of Iran. East Mediterr Health J 2000; 6: 1114-6.
10. Alizadeh AH, Ranjbar M, Ansari S, Alavian SM, Shalmani HM, Hekmat L, et al. Intra-familial prevalence of hepatitis B virologic markers in HBsAg positive family members in Nahavand, Iran. World J Gastroenterol 2005; 11: 4857-60.
11. Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003; 157: 467-71.
12. Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users. Public Health Rep 2002; 117: S126-34.
13. Diaz T, Edwards V, Susser E, Vlahov D. High prevalence of hepatitis C among young injection drug users in Harlem, New York City. 127th Annual Meeting of the American Public Health Association 1999: 9-11.
14. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses' Am J Public Health 1996; 86: 655-61.
15. Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health 2004; 94: 1218-23.
16. Cook PA, McVeigh J, Syed Q, Mutton K, Bellis MA. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction 2001; 96: 1787-97.
17. Budd J, Robertson R, Elton R. Hepatitis B vaccination and injecting drug users. Br J Gen Pract 2004; 54: 444-7.
18. Popper H. The relation between hepatitis B virus infection and hepatocellular carcinoma, Hepatogastroenterology 1986; 33: 2-5.
19. Beasley RP, Hwang LY. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 1984; 4: 113-21.
20. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
21. Dhopesh VP, Taylor KR, Burke WM. Survey of hepatitis B and C in addiction treatment unit. Am J Drug Alcohol Abuse 2000; 26: 703-7.
22. Des Jarlais DC, Perils TE, Friedman SR, Rockwell R. HIV, HBV and HCV in a cohort of drug injectors in New York City. 127th Annual Meeting of the American Public Health Association 1999: 9-11.
23. Shirin T, Ahmed T, Iqbal A, Islam M, Islam MN. Prevalence and risk factors of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infections among drug addicts in Bangladesh. J Health Popul Nutr 2000; 18: 145-50.
24. Njoh J. The prevalence of hepatitis B surface antigen (HBsAg) among drug-dependent patients in Jeddah, Saudi Arabia. East Afr Med J 1995; 72: 198-9.
25. Santana Rodriguez OE, Male Gil ML, Hernandez Santana JF, Liminana Canal JM, Martin Sanchez AM. Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Eur J Epidemiol 1998; 14: 555-61.
26. Shapatava E, Nelson KE, Tsertsvadze T, del Rio C. Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend 2006; 82: S35-8.
27. Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect 2001; 127: 475-84.
28. Maher L, Chant K, Jalaludin B, Sargent P. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. J Gastroenterol Hepatol 2004; 19: 1114-20.
29. Craine N, Walker AM, Williamson S, Brown A, Hope VD. Hepatitis B and hepatitis C seroprevalence and risk behaviour among community-recruited drug injectors in North West Wales. Commun Dis Public Health 2004; 7: 216-9.
30. Wylie JL, Shah L, Jolly AM. Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada. BMC Public Health 2006; 6: 229.
31. Seal KH, Ochoa KC, Hahn JA, Tulsky JP, Edlin BR, Moss AR. Risk of hepatitis B infection among young injection drug users in San Francisco: opportunities for intervention. West J Med 2000; 172: 16-20.
32. Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, et al. Gender dfferences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health 2003; 80: 1:37-46.